Metabolomics: A novel approach to early and noninvasive prostate cancer detection

Roberts, Matthew J., Schirra, Horst J., Lavin, Martin F. and Gardiner, Robert A. (2011) Metabolomics: A novel approach to early and noninvasive prostate cancer detection. Korean Journal of Urology, 52 2: 79-89. doi:10.4111/kju.2011.52.2.79

Attached Files (Some files may be inaccessible until you login with your UQ eSpace credentials)
Name Description MIMEType Size Downloads

Author Roberts, Matthew J.
Schirra, Horst J.
Lavin, Martin F.
Gardiner, Robert A.
Title Metabolomics: A novel approach to early and noninvasive prostate cancer detection
Journal name Korean Journal of Urology
ISSN 2005-6737
Publication date 2011-02
Sub-type Critical review of research, literature review, critical commentary
DOI 10.4111/kju.2011.52.2.79
Volume 52
Issue 2
Start page 79
End page 89
Total pages 11
Editor Kwangsung Park
Place of publication Kangnnam-gu, Seoul, Korea, Republic of
Publisher Daihan Binyogigwa Haghoi
Collection year 2012
Language eng
Formatted abstract
Prostate cancer (PCa) is the most commonly diagnosed visceral cancer in men and is responsible for the second highest cancer-related male mortality rate in Western countries, with increasing rates being reported in Korea, Japan, and China. Considering the low sensitivity of prostate-specific antigen (PSA) testing, it is widely agreed that reliable, age-independent markers of the presence, nature, and progression of PCa are required to facilitate diagnosis and timely treatment. Metabolomics or metabonomics has recently emerged as a novel method of PCa detection owing to its ability to monitor changes in the metabolic signature, within biofluids or tissue, that reflect changes in phenotype and function. This review outlines the physiology of prostate tissue and prostatic fluid in health and in malignancy in relation to metabolomics as well as the principles underlying the methods of metabolomic quantification. Promising metabolites, metabolic profiles, and their correlation with the presence and stage of PCa are summarized. Application of metabolomics to biofluids and in vivo quantification as well as the direction of current research in supplementing and improving current methods of detection are discussed. The current debate in the urology literature on sarcosine as a potential biomarker for PCa is reviewed and discussed. Metabolomics promises to be a valuable tool in the early detection of PCa that may enable earlier treatment and improved clinical outcomes.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keyword Biological markers
Prostatic neoplasms
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Published online 2011 February 19.

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: UQ Centre for Clinical Research Publications
School of Chemistry and Molecular Biosciences
School of Medicine Publications
Version Filter Type
Citation counts: Scopus Citation Count Cited 30 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 22 Mar 2011, 13:26:02 EST by Dr Horst Joachim Schirra on behalf of UQ Centre for Clinical Research